Cowen Downgrades Y-mAbs Therapeutics (YMAB) to Market Perform 'As Pipeline Clarifies; Restructuring Announced' Jan 5, 2023 05:31AM
Cowen Reiterates Y-mAbs Therapeutics (YMAB) at Outperform, Both Danyelza and Rest of Pipeline Continue to Progress Feb 25, 2022 02:08PM
UPDATE: Y-mAbs Therapeutics (YMAB) Reiterated at Outperform by Cowen, Progress is Encouraging, Shares are Undervalued Feb 11, 2022 10:05AM
Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference Mar 8, 2019 09:03AM
Cowen Starts Y-mAbs Therapeutics (YMAB) at Outperform Oct 16, 2018 06:21AM


Sep 25, 2018 04:39PM Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 21, 2018 11:03AM Y-mAbs Therapeutics (YMAB) IPO Opens 67% Higher
Sep 21, 2018 05:49AM Y-mAbs Therapeutics, Inc. Prices 6M Share IPO at $16/Sh
Sep 20, 2018 08:25PM Y-mAbs Therapeutics Announces Pricing of Initial Public Offering